The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Current Treatment Strategies for Disseminated Candidiasis
Abstract
The incidence of disseminated candidiasis has increased dramatically over the past several decades. Fortunately, in recent years, a variety of new antifungal agents have become available to treat these infections. On the basis of efficacy, safety, and cost considerations, fluconazole is the agent of choice for the empirical treatment of disseminated candidiasis in nonneutropenic, hemodynamically stable patients, unless a patient is suspected to be infected with an azole-resistant species (i.e., Candida glabrata or Candida krusei). For hemodynamically unstable or neutropenic patients, agents with broader species coverage, such as polyenes, echinocandins, or, possibly, voriconazole, are preferred for empirical treatment of candidemia. Modification of the initial, empirical regimen depends on the response to therapy and the subsequent identification of the species of the offending pathogen. Echinocandins or high-dose polyenes are preferred for the treatment of infections with C. glabrata or C. krusei. Central venous catheters should be removed from all patients who have disseminated candidiasis, if feasible, and antifungal therapy should be administered to all patients who have candidemia or proven candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationHajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Edwards, Jr., Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/514504 · Cited by 418
Self-citationBreakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/423274 · Cited by 402
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Pfaller, M. A., Messer, S. A., Boyken, L., Hollis, R. J., Rice, C., Tendolkar, S., & Diekema, D. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.008 · Cited by 234
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1723-1727.2002 · Cited by 232
Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Mechanism of Fluconazole Resistance in Candida krusei
Orozco, A. S., Higginbotham, L. M., Hitchcock, C. A., Parkinson, T., Falconer, D., Ibrahim, A. S., Ghannoum, M. A., & Filler, S. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2645 · Cited by 218
Self-citationOstrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., & Hollis, R. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1440-1446.2003 · Cited by 185
Marr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145
Fleming, R. V., Kantarjian, H. M., Husni, R., Rolston, K. V. I., Lim, J. T., RAAD, I. I., Pierce, S. A., Cortes, J. E., & Estey, E. H. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097650 · Cited by 134
Cuenca‐Estrella, M., Rodríguez-Pardo, D., Almirante, B., Morgan, J., Planes, A. M., Almela, M., Mensa, J., Sánchez, F., Ayats, J., Giménez, M., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh548 · Cited by 133
Antoniadou, A., Torres, H. A., Lewis, R. E., Thornby, J. A., Bodey, G. P., Tarrand, J. P., Han, X.-Y., Rolston, K. V. I., Safdar, A., RAAD, I. I., et al. (2003) · Medicine · doi:10.1097/01.md.0000091182.93122.8e · Cited by 130
Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata
Parkinson, T., Falconer, D. J., & Hitchcock, C. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1696 · Cited by 129
Colombo, A. L., Perfect, J. R., DiNubile, M. J., Bartizal, K. F., Motyl, M. R., Hicks, P. S., Lupinacci, R. J., Sable, C. A., & Kartsonis, N. A. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0973-8 · Cited by 126
Voriconazole Salvage Treatment of Invasive Candidiasis
Ostrosky-Zeichner, L. L., Lashof, A. M. L. O., Kullberg, B. J., & Rex, J. H. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1014-3 · Cited by 125
Patterns of Amphotericin B Killing Kinetics against Seven Candida Species
Cantón, E., Pemán, J., Gobernado, M., Viudes, A., & Espinel‐Ingroff, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2477-2482.2004 · Cited by 121
Prospective Study of Candida Species in Patients at a Comprehensive Cancer Center
Safdar, A., Chaturvedi, V. P., Cross, E. W., Park, S., Bernard, E. M., Armstrong, D., & Perlin, D. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2129-2133.2001 · Cited by 111
Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei
Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1213-1219.2003 · Cited by 97
Self-citationJuster‐Reicher, A., Leibovitz, E., Linder, N., Amitay, M., Flidel‐Rimon, O., Even-Tov, S., Mogilner, B. M., & Barzilai, A. (2000) · Infection · doi:10.1007/s150100070040 · Cited by 95
Safdar, A., van Rhee, F., Henslee-Downey, J., Singhal, S., & Mehta, J. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703252 · Cited by 93
Pfaller, M. A., Messer, S. A., & Hollis, R. J. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90106-6 · Cited by 86 · cited 1×
“Although rarely encountered clinically, Candida lusitaniae strains may be resistant to amphotericin [42], and clinical failures have been noted in association with amphotericin therapy [19].”
Zaoutis, T. E., Foraker, E., McGowan, K. L., Mortensen, J. E., Campos, J. M., Walsh, T. J., & Klein, J. D. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.03.002 · Cited by 56
Swinne, D., Watelle, M., der Flaes, M. V., & NOLARD, N. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.00971.x · Cited by 51
Mondal, R. K., Singhi, S. C., Chakrabarti, A., & Jayashree, M. (2004) · Pediatric Critical Care Medicine · doi:10.1097/01.pcc.0000144712.29127.81 · Cited by 45
Drago, M., Scaltrito, M. M., Morace, G., & GISIA-2 Group (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1174-9 · Cited by 45
The pathophysiology and treatment of Candida sepsis
Spellberg, B. J., & Edwards, J. E. (2002) · Current Infectious Disease Reports · doi:10.1007/s11908-002-0005-3 · Cited by 37
Self-citationBlau, I., & Fauser, A. A. (2000) · Mycoses · doi:10.1046/j.1439-0507.2000.00577.x · Cited by 30
Amphotericin B: Is a Lipid‐Formulation Gold Standard Feasible?
Spellberg, B. J., Witt, M. D., & Beck, C. K. (2004) · Clinical Infectious Diseases · doi:10.1086/380844 · Cited by 19
Self-citationSafdar, A., Armstrong, D., Cross, E. W., & Perlin, D. S. (2002) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(02)90111-6 · Cited by 11
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Human dectin-1 deficiency and mucocutaneous fungal infections
Ferwerda, B., Ferwerda, G., Plantinga, T. S., Willment, J. A., van Spriel, A. B., Venselaar, H., Elbers, C. C., Johnson, M. D., Cambi, A., Huysamen, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901053 · Cited by 752
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Self-citation
Metadata
- Authors
- Spellberg, B. J., Filler, S. G., & Edwards, J. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-15
- Volume
- 42
- Issue
- 2
- Pages
- 244-251
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2105978586
- Cited by
- 256
- References
- 44
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.